A retrospective, observational study assessing the patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm positive Non-small cell lung cancer
Latest Information Update: 16 Feb 2022
At a glance
- Drugs Erlotinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 16 Feb 2022 New trial record
- 01 Jan 2022 Results published in the Current Medical Research and Opinion